Literature DB >> 30713961

Apomorphine-Induced Immune Hemolytic Anemia.

Begoña Venegas Pérez1, Teresa Arquero Portero2, María Soledad Sánchez Fernández2, Cici Feliz Feliz1, Javier Del Val Fernández1, Pedro José García-Ruiz1.   

Abstract

Entities:  

Keywords:  apomorphine; drug‐induced anemia; hemolytic anemia

Year:  2016        PMID： 30713961      PMCID： PMC6353508          DOI： 10.1002/mdc3.12373

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  15 in total

1.  Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.

Authors:  Alice J Manson; Kirsten Turner; Andrew J Lees
Journal:  Mov Disord       Date:  2002-11       Impact factor: 10.338

2.  Hemolytic anemia secondary to mesantoin.

Authors:  I SNAPPER; D MARKS; L SCHWARTZ; L HOLLANDER
Journal:  Ann Intern Med       Date:  1953-09       Impact factor: 25.391

3.  Pathology consultation on drug-induced hemolytic anemia.

Authors:  Arand Pierce; Theresa Nester
Journal:  Am J Clin Pathol       Date:  2011-07       Impact factor: 2.493

4.  Subcutaneous apomorphine in the treatment of Parkinson's disease.

Authors:  J P Frankel; A J Lees; P A Kempster; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

Review 5.  Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007.

Authors:  George Garratty; Patricia A Arndt
Journal:  Immunohematology       Date:  2014

Review 6.  How I treat autoimmune hemolytic anemias in adults.

Authors:  Klaus Lechner; Ulrich Jäger
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

Review 7.  Immune hemolytic anemia associated with drug therapy.

Authors:  George Garratty
Journal:  Blood Rev       Date:  2010-07-21       Impact factor: 8.250

Review 8.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  The role of subcutaneous infusion of apomorphine in Parkinson's disease.

Authors:  Karoline Wenzel; Carl Nikolaus Homann; Giovanni Fabbrini; Carlo Colosimo
Journal:  Expert Rev Neurother       Date:  2014-06-11       Impact factor: 4.618

10.  The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma.

Authors:  Fatih Gürbüz; Begül Yağcı-Küpeli; Yılmaz Kör; Bilgin Yüksel; Suzan Zorludemir; Berrak Bilginer Gürbüz; Serhan Küpeli
Journal:  J Pediatr Endocrinol Metab       Date:  2014-01       Impact factor: 1.634
View more
  2 in total

Review 1.  Movement Disorders and Hematologic Diseases.

Authors:  Roshni Abee Patel; Deborah A Hall; Sheila Eichenseer; Meagan Bailey
Journal:  Mov Disord Clin Pract       Date:  2020-12-29

Review 2.  Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

Authors:  Federico Carbone; Atbin Djamshidian; Klaus Seppi; Werner Poewe
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.